PTU-144 The influence of gastric cancer screening upon stage at diagnosis and survival. (22nd June 2015)

• Record Type: Journal Article
• Authors: Markar, SR; Khanderia, E; Acharya, A; Hanna, GB
• Is Part Of: Gut. Volume 64(2015)Supplement 1
• Page Start: A126
• Page End: A126
• Publication Date: 2015-06-22
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2015-309861.259
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: Gastric is the fifth most common cancer and second most common cause of cancer-related death worldwide. The aim of this review is to evaluate the effect of gastric cancer screening upon stage at diagnosis and survival from disease. Method: A systematic review of the literature between January 1995 and December 2014 was performed. All studies that compared screened vs. non-screened populations for the diagnosis of gastric cancer and included an outcome of stage at diagnosis were analysed. The QUADAS-2 tool was used to assess the quality of the studies. Results: 11 studies comprising 4039 in the screened and 6635 in non-screened groups were included. Screening was associated with a significant increase in the detection of early gastric cancer (POR = 3.90; 95% C. I. 3.01 to 5.06; P < 0.0001) and reduction in the incidence of advanced gastric cancer (POR = 0.27; 95% C. I. 0.20 to 0.35; P < 0.0001). Furthermore screening significantly improved 5-year survival (POR = 0.56; 95% C. I. 0.48 to 0.66; P < 0.0001). The overall diagnostic accuracy for barium radiography was good as illustrated by summary ROC analysis with an area under the curve of 0.95 ± 0.01. QUADAS-2 assessment highlighted potential biases within the reference standards. Conclusion: Screening for gastric cancer is useful in detecting asymptomatic patients with early gastric cancer in high prevalence areas. This in turn, increases the number of treatable cancers and improves five-year survival. There is a need for the development and validation of alternative risk-stratification tools in low incidence areas to allow for similar benefits. Disclosure of interest: None Declared.